1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6E4EC530C767B04BC85257A69005D9AC8
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/health-outcomes-liaison-group-structure-and-activities?opendocument
18
19opendocument
20107.23.176.162
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Health Outcomes

Health Outcomes Liaison Excellence: HOL Group Structure and Activities in the Healthcare Sector

ID: 5218


Features:

12 Info Graphics

18 Data Graphics

165+ Metrics

6 Narratives

4 Best Practices


Pages/Slides: 38


Published: Pre-2013


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Health Outcomes Liaison Excellence: HOL Group Structure and Activities in the Healthcare Sector"

STUDY OVERVIEW

Biopharmaceutical and medical device companies in the current outcomes-focused market depend increasingly upon Health Outcomes Liaison (HOL) staff to serve as a scientific bridge with payer organizations, thought leaders, clinical investigators and other important healthcare decision makers. As the demand for outcomes and comparative effectiveness data grows, successful companies will need to know how to fully leverage the relatively new field-based HOL function.


Best Practices, LLC, conducted this study to help pharma and biotech executives and managers identify how leading companies structure their HOL programs in an increasingly challenging business environment. The research also examines best practices in HOL management and identifies the ideal background, in education and experience, needed for an HOL to succeed. Leaders burdened with headcount constraints and insufficient resources to support new products can potentially gain critical efficiencies through the shrewd use of HOLs.


KEY TOPICS

  • Health Outcome Liaison Program Span & Scope
  • Health Outcome Liaison Program Resources
  • Health Outcome Liaison Background & Experience
  • Health Outcome Liaison Activities
  • Health Outcome Liaison Involvement Over Lifecycle of Drugs

SAMPLE KEY METRICS
  • Longevity of Health Outcome Liaison group
  • Health Outcome Liaison reporting structure
  • Health Outcome Liaison executive oversight
  • Geographic span in which companies employ Health Outcome Liaisons
  • Total estimated budget for company’s Health Outcome Liaison program for the last fiscal year
  • Size of HOL program
  • Most common Therapeutic Areas in which HOLs are employed
  • Ratio of products per HOL
  • Preferred level of education required to become an HOL
  • Typical HOL compensation levels based upon experience
  • Frequency of ongoing training provided to HOLs

SAMPLE KEY FINDINGS
  • On Average, HOL Programs Are Less than Five Years Old: The majority of Health Outcome Liaison programs are in their early development, with only 25% of respondents indicating that their programs have been in place for seven years or longer.

  • Generalist Model Fosters Better Interactions: Executives favored a generalist over a specialist model for HOLs, with HOLs representing the entire book of business to their diverse customers. Generalists provide clients with the convenience of “one-stop shopping.” HOLs also gain credibility with customers when they are well-rounded and knowledgeable in multiple areas. Successful generalists are trained for deep as well as broad knowledge.
METHODOLOGY

Best Practices, LLC engaged 23 HOL program leaders from 19 different pharmaceutical and medical device companies. In addition, deep-dive interviews were conducted with five participating companies to gather additional insights.

Industries Profiled:
Biotech; Pharmaceutical; Medical Device; Health Care; Chemical; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Amgen; Becton Dickinson; Boehringer Ingelheim; Cubist; Daiichi-Sankyo; Endo; Fresenius; Genentech; GlaxoSmithKline; Janssen; Medivation; Merck & Co.; Merck Serono; Pacira; Peloton; Sanofi; Sanofi Pasteur; Shire; Teva


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.